Amgen Inc.

Radius Pharmaceuticals, Inc.

Microchip Technology Inc.

Insys Development Company, Inc.

Fresh Cut Development, LLC

Hung Q Nguyen

Shaw-Fen Sylvia Hu

Kenneth William Walker

Leslie Phillip Miranda

John Kevin Sullivan

Joseph G McGivern

Colin Victor Gegg, Jr

Venkat R Goskonda

Francis Hall Martin

Ningxin Yan

Kiran Kumar Vangara

Beverly S Adler

Taruna Arora Khare

Huaguang Li

Colin V Gegg

Stefan I McDonough

Chadwick Terence King

James B Nolan

Gary Elliott

Scott Michael Silbiger

Shuqian Jing

Gordon Ng

Eugene Medlock

Richard Yeh

Brian Dellacroce

Jeannie Jung

Ningxin Yin

Gary S Elliott

Gary S Elliot

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Stable cannabinoid formulations

The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.

Methods and compositions relating to anti-CCR7 antigen binding proteins

Disclosed is a DNA encoding a composition of matter of the formula(X)&#x2014;(F)&#x2014;(X)&#x2014;(F)&#x2014;(X)&#x2003;&#x2003;(I)and multimers thereof, in which Fand Fare half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X, X, and Xare each independently -(L)-P-(L)-, and f and g are each independently 0 or 1; P is a ShK peptide analog of no more than about 80 amino acid residues in length; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. A DNA encoding the ShK peptide analog is disclosed. Also disclosed are an expression vector comprising the DNA, and a host cell comprising the expression vector.

Toxin peptide therapeutic agents

Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

Methods of using conjugated toxin peptide therapeutic agents

DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression

Disclosed is a composition of matter of the formula(X)&#x2014;(F)&#x2014;(X)&#x2014;(F)&#x2014;(X)&#x2003;&#x2003;(I)and multimers thereof, in which Fand Fare half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X, X, and Xare each independently -(L)-P-(L)-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

Conjugated toxin peptide therapeutic agents

The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.

IL-17 receptor like molecules and uses thereof

A microcontroller for use in battery charging and monitoring applications is disclosed. The microcontroller includes a microprocessor and various front-end analog circuitry such as a slope A/D converter and a multiplexer for allowing a plurality of analog input signals to be converted to corresponding digital counts indicative of signal level. In order to make the measurements of the selected analog inputs more precise, the microcontroller uses a unique calibration procedure whereby selected parameters associated with the analog circuitry that are subject to variation are measured during test and corresponding calibration constants are calculated therefrom and stored in program memory. These stored calibration constants are subsequently used by the microprocessor in conjunction with the digital counts of the analog input signals for calculating a more precise measurement of the analog input signals.

Digital trimming of on-chip analog components

Growing community of inventors

Thousand Oaks, CA, United States of America

Hung Q Nguyen